Towt J, Tsai S C, Hernandez M R, Klimov A D, Kravec C V, Rouse S L, Subuhi H S, Twarowska B, Salamone S J
International Drug Monitoring Business Unit, Roche Diagnostic Systems, Inc., Somerville, NJ 08876, USA.
J Anal Toxicol. 1995 Oct;19(6):504-10. doi: 10.1093/jat/19.6.504.
We developed a rapid, sensitive, and simple-to-use multi-analyte diagnostic device for the detection of drugs of abuse in urine: the ONTRAK TESTCUP. No sample or reagent handling is necessary with this device, and the device also serves as the sample collection cup. The TESTCUP contains immunochromatographic reagents that qualitatively and simultaneously detect the presence of benzoylecgonine, morphine, and cannabinoids (delta9-tetrahydrocannabinol [THC] in urine. It is based on the principle of competition between the drug in the sample and membrane- immobilized drug conjugate for antidrug antibodies coated on blue-dyed microparticles. Each drug assay has its own strip, which contains an antibody specific to benzoylecgonine, morphine, or THC. A sample is collected in the TESTCUP, a lid is placed on it, and a chamber at the top of the cup is filled with urine by inverting the cup for 5 s. Urine proceeds down immunochromatographic strips, and the assays are developed. In approximately 3-5 min, the Test Valid bars appear, a decal is removed from the detection window, and the results are interpreted. The appearance of a colored bar at the detection window for each drug indicates a negative result. The absence of color in any specific drug detection window indicates a positive result for that drug. If a positive result is obtained, the same device (cup) can be used for gas chromatographic-mass spectrometric (GC-MS) confirmation. When the precision of the TESTCUP was evaluated, the results obtained were as follows: for urine controls containing drug at 50% of its cutoff concentration, the results were greater than or equal to 96, 98, and 96% negative for benzoylecgonine, morphine, and THC, respectively; for urine controls containing drug at 120% of its cutoff concentration, the results were greater than or equal to 97, 100, and 98% positive for benzoylecgonine, morphine, and THC, respectively. The correlations of clinical sample results using the TESTCUP versus results by GC-MS and the ONTRAK and OnLine assays were assessed. There was 100% agreement between samples prescreened positive by GC-MS and positive by TESTCUP for all three assays. There was 100% agreement between TESTCUP and ONTRAK results and between TESTCUP and OnLine results when testing clinical samples positive and negative for cocaine (benzoylecgonine) or THC. Greater than 99% agreement was observed between TESTCUP and ONTRAK results and between TESTCUP and OnLine results when testing clinical samples positive and negative for morphine. The cross-reactivity of the TESTCUP assay to related drugs and drug metabolites was also determined, and the results were similar to those of the ONTRAK and OnLine assays.
我们开发了一种快速、灵敏且易于使用的多分析物诊断设备,用于检测尿液中的滥用药物:ONTRAK TESTCUP。使用该设备无需进行样本或试剂处理,并且该设备还兼作样本收集杯。TESTCUP包含免疫层析试剂,可定性并同时检测尿液中苯甲酰芽子碱、吗啡和大麻素(δ9-四氢大麻酚[THC])的存在。它基于样本中的药物与固定在膜上的药物偶联物竞争包被在蓝色染料微粒上的抗药物抗体的原理。每种药物检测都有自己的试纸条,其中包含针对苯甲酰芽子碱、吗啡或THC的特异性抗体。在TESTCUP中收集样本,盖上盖子,将杯子倒置5秒钟,使杯子顶部的腔室充满尿液。尿液顺着免疫层析试纸条流下,检测过程展开。大约3至5分钟后,测试有效条出现,从检测窗口移除贴纸并解读结果。每个药物在检测窗口出现有色条表示阴性结果。任何特定药物检测窗口无色表示该药物检测结果为阳性。如果获得阳性结果,可使用同一设备(杯子)进行气相色谱-质谱(GC-MS)确认。评估TESTCUP的精密度时,得到的结果如下:对于药物浓度为其临界浓度一半的尿液对照,苯甲酰芽子碱、吗啡和THC的阴性结果分别大于或等于96%、98%和96%;对于药物浓度为其临界浓度120%的尿液对照,苯甲酰芽子碱、吗啡和THC的阳性结果分别大于或等于97%、100%和98%。评估了使用TESTCUP得到的临床样本结果与GC-MS以及ONTRAK和OnLine检测结果之间的相关性。对于所有三种检测,GC-MS预筛选为阳性且TESTCUP检测为阳性的样本之间完全一致。在检测可卡因(苯甲酰芽子碱)或THC呈阳性和阴性的临床样本时,TESTCUP与ONTRAK结果之间以及TESTCUP与OnLine结果之间完全一致。在检测吗啡呈阳性和阴性的临床样本时,TESTCUP与ONTRAK结果之间以及TESTCUP与OnLine结果之间的一致性超过99%。还确定了TESTCUP检测对相关药物和药物代谢物的交叉反应性,结果与ONTRAK和OnLine检测相似。